Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · 2014
[Applying of recombinant interleukin-1β to treat chronic hepatitis C for patients non-response to the previous antiviral therapy].
Клиническое исследованиеСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fazylov V Kh, Tkacheva S V, Manapova É R
Аннотация
UNLABELLED: The search for rational treatment of CHC patients, non-response to the primary antiviral therapy especially with unfavorable genotypes for interleukin-28B, remains valid.
PURPOSE: To evaluate the efficacy and safety of recombinant IL-1β (Betaleukin) in combined antiviral therapy in patients with chronic hepatitis C who did not respond to previous treatment. The study included 26 patients with HCV-1. Patients were divided into 2 groups depending on retreatment scheme: group 1 (n = 10) was treated with recombinant IFN-a2b ("Interal"-P) 5 million IU daily subcutaneously for 12 weeks then every other day until the end of treatment; ribavirin, depending on body weight (800-1200 mg/day) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day for 12 weeks (45 injections); group 2 (n = 16)--recombinant IFN-a2b ("Interal"-P) 3 million IU every other day subcutaneously for 48 weeks; ribavirin--1000 mg/day (for a body weight < 75 kg), 1200 mg/day (for a body weight > 75 kg) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day, five courses for 3 weeks (50 injections).
RESULTS: Combined antiviral therapy (α-IFN2b and RIB) with IL-1β (Betaleukin) in patients who had not responded to previous therapy, with a predominance of unfavorable genetic background for IL-28B typing helped to improve SVR (44%) with more efficient 45-day administration of the medications in the first 12 weeks in combination with inductive α-IFN therapy and achieve biochemical response at week 24 of treatment. Adverse effects of the IL-1β mainly limited with fever, moderate local reactions and do not require discontinuation of treatment.
PURPOSE: To evaluate the efficacy and safety of recombinant IL-1β (Betaleukin) in combined antiviral therapy in patients with chronic hepatitis C who did not respond to previous treatment. The study included 26 patients with HCV-1. Patients were divided into 2 groups depending on retreatment scheme: group 1 (n = 10) was treated with recombinant IFN-a2b ("Interal"-P) 5 million IU daily subcutaneously for 12 weeks then every other day until the end of treatment; ribavirin, depending on body weight (800-1200 mg/day) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day for 12 weeks (45 injections); group 2 (n = 16)--recombinant IFN-a2b ("Interal"-P) 3 million IU every other day subcutaneously for 48 weeks; ribavirin--1000 mg/day (for a body weight < 75 kg), 1200 mg/day (for a body weight > 75 kg) and "Betaleukin" subcutaneously 0.005 mcg/kg every other day, five courses for 3 weeks (50 injections).
RESULTS: Combined antiviral therapy (α-IFN2b and RIB) with IL-1β (Betaleukin) in patients who had not responded to previous therapy, with a predominance of unfavorable genetic background for IL-28B typing helped to improve SVR (44%) with more efficient 45-day administration of the medications in the first 12 weeks in combination with inductive α-IFN therapy and achieve biochemical response at week 24 of treatment. Adverse effects of the IL-1β mainly limited with fever, moderate local reactions and do not require discontinuation of treatment.